FIELD: medicine; psychiatry.
SUBSTANCE: invention can be used to predict the risk of developing hyperprolactinemia in women with schizophrenia taking antipsychotic therapy. The Rees-Eysench index is determined and at its value of 96.8–110.8, corresponding to the mesosthenic constitutional-morphological type, a high probability of developing hyperprolactinemia is predicted.
EFFECT: method makes it possible to predict the risk of hyperprolactinemia during antipsychotic therapy in women with schizophrenia.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING DEVELOPMENT OF VISCERAL OBESITY IN PATIENTS WITH SCHIZOPHRENIA RECEIVING QUETIAPINE THERAPY | 2017 |
|
RU2659638C1 |
| METHOD FOR PREDICTION OF METABOLIC SYNDROME DEVELOPMENT IN SCHIZOPHRENIC PATIENTS RECEIVING ANTIPSYCHOTIC THERAPY | 2018 |
|
RU2703424C1 |
| METHOD FOR SUPPORTING MEDICAL DECISIONS ON SELECTION OF ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA IN ORDER TO PREVENT AKATHISIA | 2021 |
|
RU2756614C1 |
| METHOD FOR PREDICTION OF METABOLIC SYNDROME RISK WITH UNDERLYING ANTIPSYCHOTIC THERAPY IN SCHIZOPHRENIC PATIENTS | 2019 |
|
RU2722649C1 |
| METHOD FOR PREDICTING NEGATIVE CLINICAL MANIFESTATIONS IN SCHIZOPHRENIA FLOW | 2001 |
|
RU2188577C1 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF TREATMENT OF PATIENTS WITH SCHIZOPHRENIA | 2021 |
|
RU2775440C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF SCHIZOPHRENIA IN MEN WITH PAROXYSMAL ENDOGENOUS PSYCHOSES MANIFESTING AT AGE FROM 18 TO 25 YEARS | 2018 |
|
RU2685549C1 |
| DIAGNOSTIC TECHNIQUE FOR METABOLIC SYNDROME IN SCHIZOPHRENIC PATIENTS RECEIVING NEUROLEPTIC THERAPY | 2019 |
|
RU2717367C1 |
| METHOD FOR PREDICTING THE DEGREE OF RISK OF EXTRAPYRAMID SIDE EFFECTS DURING THE BACKGROUND OF HALOPERIDOL THERAPY IN PATIENTS WITH SCHIZOPHRENIC SPECTRUM DISORDERS | 2021 |
|
RU2771180C1 |
| APPLICATION OF TIZANIDINE AS DRUG-INDUCED PARKINSONISM CORRECTOR | 2008 |
|
RU2393860C2 |
